AY035
Candidate Overview
Recombinant BCG overexpressing phoP-phoR
Sponsor / Lead Developer: Anyong Dingye Biotechnology Ltd.
Primary Indication: Prevention of Mtb infection or sustained infection
Other Indication(s): Prevention of TB disease
Target Population(s): Adolescents and Adults
Target Route of Administration: Intramuscular
Immune tissue localization: Lung
Immunological responses: T-cell
Preclinical Animal Models: Guinea pig and Mouse
Intended to elicit trained immunity: Yes
Additional Immunologic Response Information
HYPOTHESIZED | DEMONSTRATED |
|
| Immune Response | T-cell | |
| T-cell phenotype | CD4 | |
| T-cell functional profile | IFN-γ |
|
| Preferential immune tissue localization | Lung | |
| Trained immunity | Yes |